Konruns Pharmaceutical Co., Ltd. (SHA: 603590) announced plans to present results from a Phase II clinical study of its KC1036 in patients with advanced thymic tumors progressing after prior platinum-based chemotherapy at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. KC1036 is a Category 1 chemical drug that demonstrates anti-tumor activity through inhibition of multiple targets, including VEGFR2 and AXL.
Clinical Study Design & Patient Population
Parameter
Detail
Study Phase
Phase II
Patient Population
Advanced thymic tumors post-platinum chemotherapy
Total Enrolled
31 patients
Thymic Carcinoma (TC)
25 patients
Thymoma (T)
6 patients
Data Cutoff
June 9, 2025
Median Follow-up
19.3 months
Efficacy Evaluable
All 31 patients
Key Efficacy Results
Thymic Carcinoma Cohort (n=25)
Endpoint
Result
Overall Response Rate (ORR)
20.0%
Disease Control Rate (DCR)
80%
Median Progression-Free Survival (PFS)
8.2 months
Median Duration of Response (DoR)
15.3 months
18-month Overall Survival (OS) Rate
75.5%
Median OS
Not yet reached
Thymoma Cohort (n=6)
Endpoint
Result
Disease Control Rate (DCR)
100%
Median Progression-Free Survival (PFS)
13.6 months
18-month Overall Survival (OS) Rate
100%
Median OS
Not yet reached
Drug Profile & Development Status
Molecule Classification: Category 1 chemical drug (novel molecular entity)
Mechanism of Action: Multi-target inhibitor targeting VEGFR2 and AXL pathways
Current Indications in Development:
Gastrointestinal tumors
Thymic tumors
Pediatric Ewing sarcoma
Safety Profile: No new safety signals observed, consistent with previously established profile
Market Context & Therapeutic Significance
Unmet Medical Need: Thymic tumors represent rare but challenging malignancies with limited treatment options after platinum-based chemotherapy failure
Clinical Differentiation: KC1036 demonstrates meaningful disease control and survival outcomes in a heavily pre-treated population
ASCO Platform: Presentation at premier oncology conference provides global visibility and scientific validation
Development Strategy: Multi-indication approach maximizes asset value across different tumor types
Competitive Landscape for Thymic Tumors
Therapeutic Approach
Current Options
KC1036 Advantage
Second-line Chemotherapy
Limited efficacy, significant toxicity
Targeted approach with manageable safety
Immunotherapy
Modest response rates in thymic carcinoma
Higher DCR (80%) in TC cohort
Anti-angiogenic Agents
Limited data in thymic tumors
Dual targeting of VEGFR2 and AXL pathways
Clinical Evidence
Sparse Phase II data available
Robust dataset with mature follow-up (19.3 months)
Forward-Looking Statements This brief contains forward-looking statements regarding clinical development, regulatory pathways, and commercial potential for KC1036. Actual results may differ due to risks including final ASCO presentation data, regulatory decisions, and competitive dynamics in the oncology landscape.-Fineline Info & Tech
By Fineline Cube